Steven Goldstein
Obstetrics & Gynecology · New York, NYNPI 1558362210
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $364,284 of the $550,849 with a category attached, or 66.1%. 24 manufacturers reported payments, led by Pfizer at 34.1% of the total. Reporting peaked in 2023 at $185,753 and has fallen 77.3% since, to $42,209 in 2025. Among obstetrics & gynecology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 266 payments — averaging $2070.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$188K
- Coopersurgical, Inc.$115K
- Astellas Pharma US Inc$77K
- Cook Incorporated$42K
- Astellas Pharma Europe Ltd$42K
- Bayer$26K
- plus $62K from 18 others
Across 31 payments — averaging $2848.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$66K
- Mylan Inc.$13K
- AbbVie$4K
- Mylan Technologies Inc.$3K
- Myovant Sciences Inc.$2K
- Amgen$189
What the payments were for
- Royalty or licence$42,3258%
- Consulting fees$364,28466%
- Speaking & faculty fees$86,76716%
- Travel & lodging$50,1779%
- Food & beverage$6,9971%
- Education$3000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 45 | $187,932 |
| Coopersurgical, Inc. | 34 | $114,761 |
| Astellas Pharma US Inc | 61 | $76,681 |
| Cook Incorporated | 2 | $42,325 |
| Astellas Pharma Europe Ltd | 24 | $41,539 |
| Bayer | 10 | $25,564 |
| Therapeuticsmd, Inc. | 24 | $21,096 |
| AbbVie | 10 | $14,156 |
| AMAG Pharmaceuticals, Inc. | 10 | $5,639 |
| Novo Nordisk | 9 | $5,214 |
| Amgen | 8 | $5,176 |
| Echonous, Inc. | 1 | $3,397 |
| Shield Therapeutics Inc | 4 | $2,691 |
| Duchesnay USA Incorporated | 3 | $2,123 |
| Scynexis, Inc. | 2 | $1,142 |
| Astellas Pharma Inc | 4 | $589 |
| Afaxys, Inc. | 1 | $338 |
| Lilly USA, LLC | 1 | $125 |
| Radius Health, Inc. | 1 | $121 |
| Myovant Sciences Inc. | 3 | $85 |
| Grifols USA, LLC | 5 | $78 |
| Mayne Pharma Commercial LLC | 2 | $32 |
| Avion Pharmaceuticals | 1 | $28 |
| Agile Therapeutics, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$550,849 in reported general payments places this provider in the 95th percentile of 2,673 obstetrics & gynecology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OsphenaOspemifene | 46 | $25,229 |
| DuaveeEstrogens,conj/Bazedoxifene | 47 | $24,416 |
| PremarinEstrogens, Conjugated | 46 | $20,779 |
| ProliaDenosumab | 12 | $20,578 |
| Estradiol | 135 | $14,920 |
| VagifemEstradiol | 19 | $9,117 |
| YuvafemEstradiol | 42 | $8,689 |
| EstringEstradiol | 14 | $7,397 |
| EvistaRaloxifene Hcl | 15 | $6,547 |
| Raloxifene Hcl | 86 | $5,404 |
| DottiEstradiol | 17 | $2,192 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 22 | $1,003 |
| ProgesteroneProgesterone, Micronized | 38 | $794 |
| Estradiol (Twice Weekly)Estradiol | 14 | $755 |
| Betamethasone Valerate | 20 | $592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerDuavee, Premarin, Estring | $187,932 | $52,591107 claims |
| Duchesnay USA IncorporatedOsphena | $2,123 | $25,22946 claims |
| AmgenProlia | $5,176 | $20,57812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,673 obstetrics & gynecology providers in New York.
Other obstetrics & gynecology in New York
- Mary PolanNew York$862K
- Veronica LernerNew York$368K
- Lisa EngNew York$219K
- Rachel MaschNew York$187K
- Amy PollackNew York$184K
- Jian Qun HuangNew York$160K
- Carolyn WesthoffNew York$143K
- Melanie MarinNew York$123K
- Amitasrigowri MurthyNew York$117K
- Suzanne FenskeNew York$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.